MedTrace Logo

Evaluating the Efficacy and Safety of Dehypotin® in the Patients With Type 2 Diabetes Mellitus or Cardiovascular Disease

NCT01108978 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2011-06-09

No results posted yet for this study

Summary

The purpose of this study is to evaluate the Efficacy and Safety of Dehypotin® in the Patients with Type 2 Diabetes Mellitus or Cardiovascular Disease. Eligible patients will be randomly assigned to 1 of 2 arms, either Dehypotin® or placebo, and will receive the diet advisement throughout the study.

Conditions

Interventions

DRUG

Placebo

Dehypotin® 40 mg/day or placebo, once a day, shortly after baseline for 12 consecutive weeks

DRUG

Dehypotin

Dehypotin® 40 mg/day or placebo, once a day, shortly after baseline for 12 consecutive weeks

Sponsors & Collaborators

  • National Taiwan University Hospital

    collaborator OTHER

  • Nang Kuang Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Yang Wei Shiung · National Taiwan University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2011-05-31
Completion
2011-05-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01108978 on ClinicalTrials.gov